Turner D M, Warson J S, Wirt T C, Scalley R D, Cochran R S, Miller K J
Front Range Center for Brain and Spine Surgery, Poudre Valley Hospital, Fort Collins, Colorado, USA.
J Spinal Disord. 1995 Jun;8(3):206-12. doi: 10.1097/00002517-199506000-00005.
The use of ketorolac was studied in patients undergoing lumbar laminectomy and those receiving lumbar fusion with or without instrumentation. Laminectomy patients in the ketorolac group used significantly less narcotic analgesic than did those in the narcotic treatment group. Ketorolac patients in both surgical categories experienced better pain control than narcotic group patients did. Laminectomy ketorolac patients experienced less sedation than did those in the narcotic group, and a similar trend was noted for fusion patients. A significant improvement in postoperative ambulation was demonstrated in the fusion ketorolac group. Postoperative total drug costs were significantly greater in both ketorolac treatment groups. A one-half day decrease in hospitalization was noted for laminectomy ketorolac patients. The overall annual financial impact of the use of ketorolac in lumbar spine patients is a net savings of $211,095.
对接受腰椎板切除术的患者以及接受腰椎融合术（无论有无内固定）的患者使用酮咯酸的情况进行了研究。酮咯酸组的腰椎板切除术患者使用的麻醉性镇痛药明显少于麻醉治疗组的患者。两个手术类别的酮咯酸治疗患者的疼痛控制情况均优于麻醉组患者。腰椎板切除术的酮咯酸治疗患者的镇静程度低于麻醉组患者，融合术患者也呈现出类似趋势。融合术的酮咯酸治疗组患者术后行走能力有显著改善。两个酮咯酸治疗组的术后总药物费用均显著更高。腰椎板切除术的酮咯酸治疗患者的住院时间减少了半天。在腰椎疾病患者中使用酮咯酸的总体年度财务影响是净节省211,095美元。
